Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Returning 1453 results

Notice of Change to Key Dates for PAR-18-721 "Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed)"

NOT
Wednesday, May 6, 2020
CounterACT
Wednesday, July 1, 2020
NOT-NS-20-064

Funding Opportunity Purpose

Notice Change Key Dates PAR-18-721 Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed)" Notice Number: NOT-NS-20-064 Key Dates Release Date: 6, 2020 Related Announcements PAR-18-721 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-721 "Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed)." Specifically, last receipt date been changed June 30, 2020 the new expiration date this FOA be July 1, 2020. Changes the FOA shown below bold italics. Currently Reads: Part 1. Overview Information Key Dates: Application Due Date(s) 30, 2018; 28, 2019; 26, 2020, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date 27, 2020 Modified Read: Part 1. Overview Information Key Dates: Application Due Date(s) 30, 2018; 28, 2019; June 30, 2020, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date July 1, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Shardell Spriggs, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: shardell.spriggs@nih.gov

Notice of Special Interest: Administrative Supplements for NIH grants to Add or Expand Research Focused on Maternal Mortality

Notice of Special Interest
Tuesday, May 5, 2020
Tuesday, June 23, 2020
333
NOT-OD-20-104

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements NIH grants Add Expand Research Focused Maternal Mortality Notice Number: NOT-OD-20-104 Key Dates Release Date: 05, 2020 First Available Due Date: 05, 2020 Expiration Date: June 23, 2020 Related Announcements PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued Office The Director, National Institutes Health OD) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) National Institute Alcohol Abuse Alcoholism NIAAA) - New participating organization of 05/08/2020 due dates on/after 05/08/2020 applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Division Program Coordination, Planning Strategic Initiatives, Office Disease Prevention ODP) Office Behavioral Social Sciences Research OBSSR) Office Research Women's Health ORWH) Purpose Office the Director the National Institutes Health NIH) announces opportunity investigators relevant active NIH-supported grants the participating Institutes listed above address scientific priorities will lay foundation the Implementing Maternal health PRegnancy Outcomes Vision Everyone IMPROVE), is development. estimated 700 women die year the U.S. conditions related or associated pregnancy childbirth highest rate among developed nations), over 50,000 women experience severe maternal morbidity SMM). response the rising maternal mortality MM) the United States U.S.), IMPROVE initiative support research how mitigate preventable MM, decrease SMM, promote health equity the U.S. IMPROVE aim use integrated approach understand biological, behavioral, sociocultural, structural factors contributing MM/SMM building evidence base improved care outcomes specific populations regions the country. IMPROVE be multipronged, innovative research initiative designed target health disparities populations disproportionately affected MM/SMM, including African American AA), American Indian/Alaskan Native AI/AN), Asian Pacific Islander, Hispanic/Latina, very young women women advanced maternal age, people disabilities. Geographical disparities social determinants health SDoH), including education, racism, socioeconomic standing also addressed the IMPROVE approach. Causes SMM MM multifaceted. the U.S., leading causes cardiovascular disease, hemorrhage, infection. Significant contributing factors include comorbid conditions e.g., diabetes, obesity, mental health issues, substance disorders) structural health care system factors. Therefore, is necessary implement comprehensive strategies address preventable contributors SMM/MM disproportionately affected populations. order rapidly improve our understanding the leading causes pregnancy-related pregnancy-associated morbidity, including SMM, MM during pregnancy, delivery, up one year post-partum to expand research development risk stratification approaches mitigation strategies, NIH soliciting submission applications Administrative Supplements active social, biobehavioral, fundamental science awards. Applicants encouraged incorporate where appropriate community partnerships focus disparities race ethnicity, age, disability status, geographic region within overarching research areas. Projects involve secondary analysis existing data collection new data. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). Applications response this NOSI should aligned one more these equally significant goal Goal 1: Incorporate community partnerships participation domestic MM pregnancy-related pregnancy-associated morbidity research resolve health disparities attain equity maternal health. Goal 2: Expand research the leading causes MM pregnancy-related pregnancy-associated morbidity the U.S. strengthen evidence-based care prevention strategies improve outcomes. Goal 3: Develop integrated understanding pregnancy-related pregnancy-associated morbidity MM causes, including underlying comorbidities, mechanisms identify preventable risk factors develop early effective interventions. Areas research interests include are limited the following: Identify determinants risk protection detect most vulnerable populations provide points intervention cardiovascular, stroke, abnormal placentation, hemorrhage, gestational diabetes, infection immunity, mental health, substance abuse research areas. Determine factors related race, ethnicity, age affect underlying leading causes, contributors, mechanisms MM/pregnancy-related pregnancy-associated morbidity. Identify multi-level individual, interpersonal, community, sociocultural) determinants maternal health disparities, well factors contribute optimal maternal outcomes high risk communities. omics” other novel technologies existing well-characterized cohorts in clinical trials pregnant women accelerate identification diagnostic, predictive, therapeutic biomarkers including brain structure function alterations) pregnancy-related adverse maternal health outcomes. Determine contribution immune system dysregulation autoimmunity during pregnancy the postpartum period leading poor pregnancy maternal health outcomes. Identify predictors contribution maternal mortality postpartum anxiety depression harmful substance and drug overdoses, including relevant environmental social factors e.g., institutional racism, access care, intimate partner violence, etc.) affect them. Develop and/or test interventions addressing stress, perinatal postpartum depression harmful substance e.g., peer support, complementary health approaches, strategies coordinate integrate OB/GYN mental health substance treatment services) assess impact maternal health outcomes. Develop approaches interventions target pregnancy-related cardiovascular disease and/or underlying cardiovascular risk factors during perinatal postnatal periods assess impact maternal health status. Identify barriers opportunities design strategies implementing clinical guidelines blood pressure management, physical activity, diet tailored high risk communities. Link establish feasibility linking existing MM/pregnancy-related pregnancy-associated morbidity datasets, electronic health records, clinical biomarker data existing national cohorts, biobank data, national surveys registries. Develop tools modify existing tools e.g. Smartwatch ECG, blood pressure, sleep monitor heart rate monitor, devices measure real-time stress level, wearable devices detect postpartum depression, predictive modeling tools, etc.) recognize pregnancy related warning signs. Identify, monitor, target pregnancy-related pregnancy-associated morbidity/MM-related ischemic stroke arterial venous), intra-cerebral hemorrhage, epilepsy, migraine, nervous system infections, headache, encephalopathy syndromes, cognitive impairment. Develop strategies enhancing community partnerships engages women their families, community healthcare providers systems, local governments identify barriers and community-specific opportunities optimal maternal health equity. Design test strategies improve interdisciplinary coordinated care, particularly during transition periods, prenatal one year postpartum prevent mortality adverse health outcomes. Applications incorporate community partnerships interdisciplinary research strongly encouraged. administrative supplements extend work awarded the parent grant, proposal needs be within scope the project is already supported. Supplements awards clinical trials allowed. Supplement applicants must demonstrate the additional NIH funding advance science and/or medicine above current funding level. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent: PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional instructions the SF424 R&R) Application Guide and PA-18-591 (or reissue) must followed, the following additions: Application Due Date(s) – June 22, 2020 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-OD-20-104” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. project budget periods must within currently approved project period the existing parent award. Individual requests be more 150,000 direct costs the entire project period. project period be limited 1 year. Research Strategy section the application limited 6 pages should include following information Discussion the scientific rationale relevance maternal mortality. Administrative supplement applications PA-18-591 must the application form package the Competition ID contains FORMS-E-ADMINSUPP”. FOA be reissued application form packages containing FORMS-F-ADMINSUPP” May 25, 2020. Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request Review Process IC conduct administrative reviews applications will be prioritized NIH staff the Maternal Mortality Task Force. Criteria: Priority be given projects incorporate community needs perspectives that focus a population disproportionately affected MM/SMM. NIH staff review following: Does work proposed address or of goals defined earlier this notice NOT-OD-20-104)? the project designed advance our understanding the mechanisms, interventions, risk profiles pregnancy-related pregnancy-associated morbidity/MM the U.S.? Does supplement propose address or of leading preventable causes pregnancy-related pregnancy-associated morbidity/MM the U.S. outlined this notice NOT-OD-20-104)? not, there strong justification addressing preventable causes? the proposal address pregnancy-related pregnancy-associated morbidity/MM one more high risk populations based race/ethnicity, age, geographic region? the work proposed within scope the active parent award? the parent award progressing satisfactorily/according planned timeline milestones? the proposed project technically feasible within supplement budget funding period? the overall strategy, methodology, analyses proposed the supplement application well-reasoned appropriate accomplish activities the proposed project period?   Inquiries Please direct inquiries to: Nahida Chakhtoura Eunice Kennedy Shriver National Institute Child Health Human Development NICHD)National Institute Child Health Human Development Telephone: 301-435-6872 Email:  nahida.chakhtoura@nih.gov Soju Chang National Center Advancing Translational Sciences NCATS) Telephone: 301-827-9206 Email: soju.chang@nih.gov Della White National Center Complementary Integrative Health Telephone: 301-827-6358 Email: whitede@mail.nih.gov Lisa Neuhold National Eye Institute Telephone: 301-451-2020 Email: lneuhold@nei.nih.gov Jyoti Dayal National Human Genome Research Institute Telephone: 301-480-2307 Email: jyotig@mail.nih.gov NHLBI IMPROVE Initiative National Heart, Lung, Blood InstituteEmail: NHLBI_IMPROVEinitiative@nhlbi.nih.gov Rosaly Correa-de-Araujo National Institute Aging Telephone: 301-496-6762 Email: rosaly.correa-de-araujo@nih.gov Juliane Caviston National Institute Allergy Infectious Diseases Telephone: 301-761-5094 Email: juliane.caviston@nih.gov Marisol Espinoza-Pintucci National Institute Arthritis Musculoskeletal Skin Diseases Telephone: 301-827-6959 Email: marisol.espinoza-pintucci@nih.gov Minki Chatterji National Institute Drug Abuse Telephone: 301-827-5435 Email: minki.chatterji@nih.gov Trinh T. Ly National Institute Deafness Other Communication Disorders Telephone: 301-435-4085 Email: trinh.ly@nih.gov Christine Maric-Bilkan National Institute Diabetes Digestive Kidney Diseases Telephone: 301-435-0486 Email: christine.maric-bilkan@nih.gov Zuzana Justinova National Institute General Medical Sciences Email: zuzana.justinova@nih.gov Lauren D. Hill National Institute Mental Health Telephone: 301-443-2638 Email: hillla@mail.nih.gov Jennifer Alvidrez National Institute Minority Health Health Disparities Telephone: 301-594-9567 Email: jennifer.alvidrez@nih.gov Adam Hartman National Institute Neurological Disorders StrokeScientific/Research Contact Telephone: 301-496-9135 Email: adam.hartman@nih.gov Richard T. Benson National Institute Neurological Disorders StrokeScientific/Research Contact Telephone: 301-827-9071 Email: richard.benson@nih.gov Chief Grants Management Officer National Institute Neurological Disorders StrokeFinancial/Grants Management Contact Email: ChiefGrantsManagementOfficer@ninds.nih.gov Sung Sug Sarah) Yoon National Institute Nursing Research Telephone: 301-402-6959 Email: sungsug.yoon@nih.gov Hua-Chuan Sim National Library Medicine Telephone: 301-594-4882 Email:   simh@mail.nlm.nih.gov Erica Spotts Office Behavioral Social Sciences Research Telephone: 301-594-2105 Email: spottse@mail.nih.gov Courtney Coombes Office the Director Telephone: 301-827-2408 Email: courtney.coombes@nih.gov Elizabeth Neilson Office Disease Prevention Telephone: 301-827-5578 Email: neilsone@mail.nih.gov Dave Thomas Office Research Women’s Health Telephone: 301-435-1313 Email: david.thomas@nih.gov Deidra Roach, M.D. National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-5820 Email: droach@mail.nih.gov

HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Reduce Stigma in Pain Management and Opioid Use Disorder (OUD) and Treatment

Notice of Special Interest
Thursday, April 23, 2020
Saturday, May 30, 2020
333
NOT-OD-20-101

Funding Opportunity Purpose

HEAL Initiative: Notice Special Interest NOSI) regarding Availability Administrative Supplements Support Strategies Reduce Stigma Pain Management Opioid Disorder OUD) Treatment Notice Number: NOT-OD-20-101 Key Dates Release Date: April 23, 2020 First Available Due Date: 29, 2020 Expiration Date: 30, 2020 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued Office Behavioral Social Sciences Research OBSSR) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Division Program Coordination, Planning Strategic Initiatives, Office Disease Prevention ODP) Office Research Women's Health ORWH) Purpose Notice Special Interest NOSI) calls research stigma the context chronic pain management opioid or opioid disorder OUD). part NIH’s Helping End Addiction Long Term HEAL) Initiative, NIH support supplements current HEAL awards address challenges people affected the opioid crisis stigma, discrimination prejudice related chronic pain management the context opioid and/or opioid disorder its treatment. NOSI calls applications integrate incorporate stigma research ongoing HEAL funded chronic pain OUD studies order address stigma is occurring the context chronic pain and/or OUD. Because stigma research require large clinical community networks, supplement program designed leverage many networks already being developed through HEAL awards. supplement program not intended support research basic processes e.g. cultural attitudes) rather result strategies enable rapid implementation changes. total up 3.5 million available supplement existing HEAL grants cooperative agreements, up 1 year, evaluate strategies reduce stigma improve treatment, management services people chronic pain and/or OUD. Supplement requests not need address possible aspects stigma the context chronic pain or OUD, it encouraged appropriate consider piloting multi-layer, multicomponent interventions address stigma these contexts. Background 50 million adults the United States chronic daily pain. 19.6 million adults experience chronic pain interferes daily life work activities. Misuse addiction opioids, including prescription pain relievers, synthetic opioids such fentanyl, heroin become serious national health crisis. than130 people die every day an opioid-related drug overdose. Stigma be barrier treatment both people chronic pain the context being treated opioids also people OUD related painful conditions. Appropriate care needed address suffering people pain and/or OUD it critical address challenges associated stigma living these conditions, seeking care support pain management and/or recovery OUD. Stigma be barrier treatment both painful conditions substance abuse. Studies suggest people chronic pain are receiving who previously received opioid treatment face stigma their healthcare providers, family, friends, coworkers, health care system, society general. Stigma also major barrier implementation programs treatments chronic pain opioid disorder, such medication assisted treatment naloxone. People chronic pain problematic opioid report significant perceived stigma associated methadone buprenorphine treatment. Stigma also lead severe consequences people chronic pain long term opioid face acute opioid withdrawal due stigma. Chronic pain often stigmatized itself some approaches address opioid crisis led stigma related addictions be also applied people chronic pain. Stigma be challenge people pain and/or substance disorders, families, caregivers, clinicians. Reducing barriers care exist because stigma crucial care people for treatment effectiveness both chronic pain management and/or OUD. Research Objectives order effectively reduce stigma related the treatment chronic pain the context the opioid crisis and/or stigma related OUD, NIH encouraging submission applications supplements active grants provide evidence-based data inform strategies reduce stigma build resilience discrimination those chronic pain and/or OUD. High priority supplements will: Analyze strategies reduce stigma, discrimination prejudice related chronic pain management and/or OUD impact areas such prevention, management treatment access effectiveness recovery; existing psychometrically validated tools measure stigma only very compelling rationales, support development any new measurement tool. Research areas interest include: Prejudice care providers undermine treatment health QOL Strategies address stigma a variety contexts includes: among healthcare providers, workplace colleagues, emergency responders, family friends others; impact internalized anticipated stigma prevention, management, treatment recovery; adaption application existing theories health related stigma chronic pain and/or OUD reducing stigma; Rather the creation new measurement tools, use psychometrically validated measures stigma other populations e.g. HIV, mental illness) their application these populations. Analyses combinations approaches are known reduce discrimination prejudice a variety situations workplace- supervisors, colleagues; family friends, healthcare providers, emergency responders, community); Strategies address internalized stigma; Approaches build resilience discrimination prejudice these populations First stage development multicomponent approaches could expanded implemented large scale multicomponent research projects. Researchers find materials related the 2017 meeting: The Science Stigma Reduction that sponsored the National Institutes Health NIH) helpful. Description circumstances which administrative supplements available. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – Applications be accepted through 29 , 2020 , 5:00 PM local time applicant organization. NOSI expires May 30 , 2020 funding consideration, applicants must include ldquo;NOT-OD-20 101” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. parent award must active the application submitted. project budget periods must within currently approved project period the existing parent award. Applications non-responsive the terms this Notice be be considered this initiative. Review criteria, addition those described PA-18-591, include following: Does PI(s)/PD(s) expertise stigma, pain management and/or addiction appropriate the study stigma chronic pain opioid use? Does application propose engage people chronic pain and/or those OUD, providers, relevant stakeholders identifying key questions regarding stigma chronic pain management opioid and treatment? successful, does application the potential be implemented broadly Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains ldquo;FORMS-F-ADMINSUPP”. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Investigators planning submit application response the NOSI strongly encouraged contact appropriate Institute Center contact listed the NOSI discuss proposed project the context the parent award. Questions specific this NOSI should sent the contact listed the NOSI. nbsp; Inquiries Please direct inquiries to: Wendy B. Smith, MA, PhD, BCBAssociate DirectorOffice Behavioral Social Sciences Research OBSSR)Tel: 301-435-3718Email: smithwe@mail.nih.gov Wendy Weber, N.D., PhD., MPHNational Center Complementary Integrative Health NCCIH)Tel: 301-402-1272Email: mailto:weberwj@mail.nih.gov Alexis Bakos, PhD., MPH., RN National Cancer Institute NCI)Tel: 240-276-6609Email: alexis.bakos@nih.gov Leslie K. Derr, Ph.D.National Institute Arthritis Musculoskeletal Skin Diseases NIAMS)Tel: 301-402-4735 Email: derrl@mail.nih.gov M. Aklin, Ph.D.National Institute Drug Abuse NIDA)Tel: 301-827-5909Email: aklinwm@nida.nih.gov Shelley Su, Ph.D.National Institute Drug Abuse NIDA)Tel: 301-402-3869Email: shelley.su@nih.gov Yolanda Vallejo, PhD.National Institute Dental Craniofacial Research NIDCR)Tel: 301-827-4655Email: Yolanda.Vallejo@nih.gov Paul L. Kimmel, MDNational Institute Diabetes Digestive Kidney Diseases NIDDK)Tel: 301-594-1409Email:  Kimmelp@mail.nih.gov Durga Mohapatra, Ph.D.National Institute Neurological Disorders Stroke NINDS)Tel: 301-827-7403Email: dp.mohapatra@nih.gov Jacqueline Lloyd, PhD, MSWOffice Disease Prevention ODP)Tel: 301-827-5559Email: lloydj2@nih.gov

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

PA
Monday, April 20, 2020
Workforce Diversity, Training, Career Development
Friday, May 29, 2020
333
PA-20-166

Funding Opportunity Purpose

The National Institutes of Health (NIH) and the Center for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Promote Training in Clinical Research on Pain (Admin Supp Clinical Trial Not Allowed)

Notice of Special Interest
Friday, April 10, 2020
Friday, July 31, 2020
333
NOT-NS-20-044

Funding Opportunity Purpose

Notice Special Interest Encourage Eligible NIH HEAL Initiative Awardees Apply Administrative Supplements Promote Training Clinical Research Pain Admin Supp – Clinical Trial Allowed) Notice Number: NOT-NS-20-044 Key Dates Release Date: April 10, 2020 First Available Due Date: 15, 2020 xpiration Date: July 31, 2020 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Center Complementary Integrative Health NCCIH) Office Strategic Coordination Common Fund) National Cancer Institute NCI) Purpose NIH Helping End Addiction Long TermSM (HEAL) Initiative aims improve our understanding, management treatment pain funding high quality scientific research this relatively understudied area medicine. the HEAL Initiative NIH meet long-term goals providing effective non-opioid options the treatment pain conditions innovative approaches treating opioid disorders, will necessary train new generation clinical pain researchers. Leveraging HEAL Initiative clinical research programs train novice researchers investigators new pain research the mechanics, techniques, best practices clinical pain research maximize impact HEAL funding both current future research endeavors. Increasing number individuals trained high quality clinical pain research a critical step toward ensuring highest impact HEAL, studies encompass broad range pain conditions have potential include, address needs of, positively impact diverse traditionally underserved patient populations. supplement existing HEAL clinical research awards intended allow exceptional graduate, post-doctoral e.g., MD, DO, DDS, PhD), early career individuals hereafter ldquo;candidates”) expand clinical pain research experience gain access the tools skills needed prepare for career clinical pain research. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – 15, 2020 July 1, 2020 5:00 PM local time applicant organization. funding consideration, applicants must include ldquo;NOT-NS-20-044” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one two years support only. Only existing awardees active HEAL Initiative Clinical Research Pain Management awards including EPPIC-Net, BACPAC, ERN, PRISM, HOPE programs) the HEAL associated Common Fund A2CPS program eligible apply. Applications supplement parent grants sites performing clinical studies be prioritized. project budget periods this supplement must within currently approved project period the parent award parent award must active not a cost extension the entire extent a supplement). A?dministrative supplement applications to PA-18-591 must the application form package the Competition ID contains ldquo;FORMS-E-ADMINSUPP”. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Research Strategy section the application limited 5 pages two additional sections/attachments, PD/PI statement a candidate statement required descriptions below). Research Strategy Research Experience Plan; 5 pages) Describe plan the candidate’s research under supplement is within scope the funded parent HEAL Initiative research project. Identify research-related experiences be new the candidate how experiences contribute the candidate’s development a clinical pain researcher enhance ability contribute a meaningful to both current future clinical pain research projects. Describe goals will achieved during supplement award period. Examples goals include gaining experience new methodologies, assessment pain management pain management techniques the research setting, recruiting study participants, acquiring and/or analyzing data, preparing manuscripts publication, applying independent research funding. the first sentence the Research Strategy, applicants requested state the parent grant awarded a HEAL Initiative award to identify specific FOA the parent grant e.g., RFA-NS-19-016) facilitate processing the supplement application. additional sections/attachments required should attached PDF documents the ldquo;Other Attachments” field. PD/PI Statement 1 page) Describe qualifications track record the PD/PI the parent grant supporting co-investigators, applicable) mentoring graduate post-doctoral trainees clinical pain research. addition, describe specific plans mentorship this candidate during proposed research experience. Candidate Statement 3 pages) candidate should describe prior research experience, clinical experience the assessment, management, treatment pain, their accomplishments. candidate should also describe short- long-term research-related goals the ways which additional research experiences outlined this supplemental application help to achieve goals. Award Budget HEAL Initiative provide support up 50,000K per year a maximum 2 years up eight awards FY2020 FY2021. Awards be used provide salary support the candidate and/or funding relevant travel coursework. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. Applications non-responsive terms this NOSI be be considered the NOSI initiative nbsp; Inquiries Please direct inquiries to: Rebecca Hommer, MDNational Institute Neurological Disorders amp; StrokeTelephone: 301-827-2257 Email: rebecca.hommer@nih.gov

Notice of Special Interestregarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2

Notice of Special Interest
Friday, April 10, 2020
Saturday, May 9, 2020
NOT-NS-20-046

Funding Opportunity Purpose

Notice Special Interest regarding Availability Administrative Supplements Urgent Competitive Revisions the Establishment Maintenance a Research Database Neurological Manifestations the SARS-CoV-2 Notice Number: NOT-NS-20-046 Key Dates Release Date: April 14, 2020 First Available Due Date: April 06, 2020 Expiration Date: 09, 2020 Related Announcements PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose NINDS issuing Notice Special Interest NOSI) highlight urgent need research the novel coronavirus SARS-CoV-2 previously termed 2019-nCoV) its associated illness, COVID-19. NINDS especially interested developing systems collect data the neurologic effects COVID-19 infection patients requiring intensive care less severely affected individuals seen health care practitioners people across U.S. the rest the world confront pandemic due SARS-CoV-2, research community should alert the possibility COVID-19 neurologic complications addition non-specific symptoms such headache dizziness. ICU patients, neurologic symptoms COVID-19 be secondary and overshadowed the severe pulmonary, cardiovascular hepatorenal dysfunction associated change level consciousness. However, are emerging reports neurologic symptomatology ranging the relatively mild anosmia dysgeusia) the extreme encephalitis, ataxia, seizures, cerebrovascular events). are also concerns possible post-viral complications acute disseminated encephalomyelitis Guillain-Barre syndrome, seen SARS MERS. is important collect, aggregate analyze data neurologic signs symptoms COVID-19 patients across spectrum disease severity across life-span, neonates/infants through elderly. Such data help us understand virus effects the brain, spinal cord nerves, including acute symptomatology potential delayed effects affected individuals. Research Objectives order rapidly improve our understanding the prevalence symptomatology SARS-CoV-2 neurologic involvement, NINDS encouraging submission applications Competitive Revisions Administrative Supplements active grants establish maintain database collects clinical information the neurological manifestations SARS-CoV-2 addresses following: Rapid establishment deployment a web-based portal individual practitioners institutions enter de-identified data neurological complications COVID-19 patients. Data must collected using established standards Common Data Elements CDEs). protocol should include implementation a set CDEs related neurologic disorders patients infected SARS-CoV-2 incorporates complements current NINDS CDEs other international standards. core CDEs should incorporate data dictionaries using NINDS CDE format https://www.commondataelements.ninds.nih.gov/), additional relevant CDEs generated a variety neurospecialty organizations, the ability capture, additional relevant patient characteristics data captured the core CDEs, submitted a computable format. addition study data IPD=individual participant data), data dictionary the study must provided. data dictionary must in computable format e.g., tab-separated-value file). CONSIDER statement provides additional guidance sharing data see https://w3id.org/CONSIDER ). portal should permit physicians update information over course the illness. Establishment a Global Unique Identifier GUID) patients entered a COVID-19 NeuroDatabase enable linkage other GUID-enabled clinical research the same individual. Establishment maintenance a COVID-19 NeuroDatabase harmonize, aggregate make collected data widely available useful analysis, following FAIR Findable, Accessible, Interoperable, Reusable) Guiding Principles. ensure maximal value the project, applicants expected use open-source tools harmonization curation whenever possible. Description circumstances which administrative supplements available. Application Submission Information Applications this initiative must submitted using of following opportunities: PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) is intended provide funds NIH grantees applying to expand scope of active grant. PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) is intended provide funds NIH grantees where work proposed the supplement fully within scope of ongoing grant. funding instrument, activity code, be same the parent award. instructions the SF424 R&R) Application Guide and PA-18-935 or PA-18-591 must followed, the following additions: Applications encouraged be submitted soon possible will accepted a rolling basis April 6, 2020 until 8, 2020 5:00 PM local time applicant organization. NOSI expires May 9, 2020. funding consideration, applicants must include ldquo;NOT-NS-20-046” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applicants must hold active U01 U24NINDS data center award. Eligible Funding Opportunity Announcements include, are limited to: RFA-NS-19-024 RFA-NS-17-02 RFA-NS-16-015 RFA-NS-13-016 RFA-NS-11-010 supplements awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) must submitted the awardee institution the original award. Applicants must the resources ability do work under supplement without critically impacting high-priority, on-going NINDS research programs. project award budget periods this revision/supplement must within currently approved project period the original/parent award original award must active not a cost extension the entire extent the supplement). Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains ldquo;FORMS-E-ADMINSUPP”. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Competitive revision applications to PA-18-935 must the application form package the Competition ID contains ldquo;NOT-NS-20-046" Research Strategy section the application limited 6 pages. Investigators planning submit application response the NOSI strongly encouraged contact program officers listed below discuss proposed project the context the original award. Applications non-responsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries to: Rebecca Hommer, MDNational Institute Neurological Disorders amp; StrokeTelephone: 301-827-2257 Email: rebecca.hommer@nih.gov

Notice of Special Interest (NOSI): Availability of Administrative Supplements to Advance Safe and Effective Therapeutics in Pregnant and Lactating Women and Children

Notice of Special Interest
Wednesday, March 25, 2020
Tuesday, June 2, 2020
333
NOT-HD-20-003

Funding Opportunity Purpose

Notice Special Interest NOSI): Availability Administrative Supplements Advance Safe Effective Therapeutics Pregnant Lactating Women Children Notice Number: NOT-HD-20-003 Key Dates Release Date: March 25, 2020 First Available Due Date: June 01, 2020 Expiration Date: June 02, 2020 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Human Genome Research Institute NHGRI) National Institute General Medical Sciences NIGMS) National Institute Neurological Disorders Stroke NINDS) National Institute Minority Health Health Disparities NIMHD) Purpose Notice Special Interest NOSI) calls research can ultimately advance safe effective therapeutics pregnant lactating women, neonates, infants. purpose this NOSI to provide seed funds support current prospective investigators generate preliminary data, collect samples, develop robust models analytic tools future novel research the NICHD's Obstetric Pediatric Pharmacology Therapeutics Branch's program priorities https://www.nichd.nih.gov/about/org/der/branches/opptb). Background Physiological changes during pregnancy resulting altered maternal drug metabolism impacted efficacy safety therapeutics pregnant women. Pregnancy induced hormonal, immunologic, metabolic changes also influence alter drug disposition. Despite research efforts have focusing pharmacokinetics medications used pregnant women the past decade, knowledge gaps exist understanding pregnancy influences drug disposition the underlying mechanisms well roles placental drug transporters. Moreover, is dearth research understanding safety effectiveness therapeutics lactating women. Administrative supplements primarily provide support stimulate scientific community conducting research pregnant lactating women. knowledge gaps also exist the understanding pediatric ontogeny influencing pharmacokinetics, pharmacodynamics dosing, funds be also available research addressing gaps knowledge specifically neonates infants. Research Objectives NOSI informs current NIH awardees NICHD interested administrative supplement applications currently funded projects supported NICHD investigators are currently funded other participating NIH ICs interested expanding moving obstetric pediatric pharmacology therapeutics research. Interested applicants encouraged expand efforts their parent grants address research topics relevant NICHD’s strategic plan Theme Five advancing safe effective therapeutics pregnant lactating women children is outlined the link: https://www.nichd.nih.gov/sites/default/files/2019-09/NICHD_Strategic_Plan.pdf Example topics include, are limited to, following: Leveraging existing resources integrative data analyses e.g., biobanks, EHRs, etc.) assess safety, effects, clinical outcomes therapeutics pregnant lactating women discover/identify novel therapeutic potentials diseases conditions these populations; Biomarkers detect/predict adverse pregnancy outcomes preventing reducing maternal morbidity mortality; Pharmacogenomic, metabolomic, microbiome approaches precision therapeutics pregnant lactating women neonates; Innovative strategies accelerate ongoing studies e.g., incorporate new analytical technical approaches, add additional study sites augment patient enrollments, etc.); Studies ontogeny drug metabolizing enzymes, transporters, and/or receptors neonates infants; silico models assess potential targets toxicities novel therapeutic strategies pregnant lactating women; Collection banking biospecimens humans i.e., cord blood, placenta, breast milk) future therapeutics research. While a research area per se, inclusion underserved understudied populations research studies encouraged. populations include racial ethnic minority groups, underserved rural populations, people less privileged socioeconomic status, along groups subject discrimination have poorer health outcomes often attributed being socially disadvantage IC-Specific Information National Institute General Medical Sciences: NIGMS support studies focused drug disposition. Work proposed supplements must fall within scope the aims the NIGMS grant be supplemented. Investigators encouraged contact NIGMS Scientific Program Officer the grant be supplemented before preparing application, discuss relevance the proposed research the parent grant to Institute's research priorities. NIGMS grantees must hold active R01 Maximizing Investigators' Research Award MIRA) R35) award the time the award. National Human Genome Research Institute: NHGRI shares interest expresses support any the current NHGRI awardees qualifies submit administrative supplement requests under NOT-HD-20-003. National Institute Minority Health Health Disparities: NIMHD welcomes applications focus clinical translational research studies pregnant lactating women infants/children minority health disparity populations African Americans, Hispanics, American Indians, Alaska Natives, Asian Americans, Native Hawaiians other Pacific Islanders, socioeconomically disadvantaged populations, rural populations). Studies not limited early detection, prevention, treatment reduce maternal infant morbidity mortality, may include identification genetic ancestral markers, pharmacokinetic pharmacodynamic biomarkers drug efficacy, drug-drug interactions drug-diet interactions, microbial profiling validation studies. National Institute Neurological Disorders Stroke: NINDS interested research relevant its mission seek fundamental knowledge the brain nervous system to that knowledge reduce burden neurological disease. addition the general areas interest listed above, areas interest specific NINDS include are limited advancing safe effective therapeutics neurological disorders pregnant lactating women, neonates, infants. Human subjects research either newly enrolled participants experiments using newly-acquired specimens the purposes this NOSI considered be of scope. Award Budget Supplement budget requests limited no than amount the current parent award cannot exceed 200,000 direct costs, exclusive Facilities Administrative costs sub-awards. Requests must reflect actual needs the proposed project. Requests for year support only. is anticipated 10-12 awards be made, subject availability funds NICHD. earliest anticipated start date August 1, 2020. Eligible Individuals Program Director/Principal Investigator) be eligible, individual(s) must hold active NIH grant the time the award. Awards No-Cost Extension NCE) not eligible. supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) submitted the awardee institution the parent award. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date – June 1, 2020, 5:00 PM local time applicant organization. funding consideration, applicants must include ldquo;NOT-HD-20-003” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. is strongly recommended the applicants contact both (1) their respective program officer(s) the Institute supporting parent award confirm ahead time the supplement falls within scope the parent award and (2) Dr. Aaron Pawlyk pawlykac@mail.nih.gov) confirm proposed request fits within scientific scope this Notice. Further, applicants strongly encouraged notify program contact the Institute supporting parent award See Table IC-Specific Information, Requirements Staff Contacts) that request been submitted response this FOA order facilitate efficient processing the request. Administrative Review Process NICHD conduct administrative reviews submitted applications will support most meritorious applications submitted consideration, pending availability funds. Criteria: the work proposed within scope the active award? the work proposed focused activities will ultimately lead advancing safe effective therapeutics pregnant lactating women, neonates, infants? the work likely stimulate additional activity leading progress towards safe effective therapeutics pregnant lactating women, neonates, infants? nbsp; Inquiries Please direct inquiries to: Aaron C. Pawlyk, Ph.D. Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) E-mail: pawlykac@mail.nih.gov

Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome

Notice of Special Interest
Tuesday, March 10, 2020
Tuesday, June 2, 2020
333
NOT-TR-20-008

Funding Opportunity Purpose

This Notice is part of the NIH Helping to End Addiction Long-Term (HEAL) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. NCATS and other participating institutes and Centers (ICs) are inviting investigators with relevant active research project grants and cooperative agreements to submit administrative supplements, according to PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional), for funded projects to identify and validate new pain and opioid use disorder (OUD) targets from within the understudied Druggable Genome.

Notice of Special Interest (NOSI): Administrative Supplements to Support Enhancement of Software Tools for Open Science

Notice of Special Interest
Tuesday, March 3, 2020
Saturday, May 16, 2020
333
NOT-OD-20-073

Funding Opportunity Purpose

Notice Special Interest NOSI): Administrative Supplements Support Enhancement Software Tools Open Science Notice Number: NOT-OD-20-073 Key Dates Release Date: March 3, 2020 First Available Due Date: 15, 2020 Expiration Date: 16, 2020 Related Announcements PA-18-591Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Administrative SupplementClinical Trial Optional) Issued Office The Director, National Institutes Health OD) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) Fogarty International Center FIC) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) National Cancer Institute NCI) Purpose Notice announces availability administrative supplements active grants focus biomedical software development have significant software development component. goal these supplements to invest research software tools recognized value a scientific community enhance impact leveraging best practices software development advances cloud computing. initiative part a plan implementing the NIH Strategic Plan Data Science, describes actions aimed modernizing biomedical research data ecosystem making data FAIR findable, accessible, interoperable, reusable) high impact open science. supplements intended support collaborations between biomedical scientists software engineers enhance design, implementation, cloud-readiness” research software. Through awards, NIH Office Data Science Strategy ODSS) intends help researchers have developed scientifically valuable software make tools sustainable, contribute open science, take advantage new data science computing paradigms. Background part their research projects, investigators often produce innovative, scientifically valuable software tools. tools enabled scientists efficiently process manage data, mine, analyze, visualize, interpret results. However, much this valuable software been built supported under conditions are longer optimal a rapidly changing landscape. Additionally, investigators lack resources adapt revise software take advantage new computing paradigms to robust, sustainable, accessible a broader community. opportunity intended help researchers redeploy research software tools be robust sustainable a shared data ecosystem envisioned the NIH ODSS. challenges considerable. example, tools developed customized data held on-premises, often optimized local computing platforms including supporting libraries) cannot readily scaled applied open science data, such those stored a cloud environment. Software tools most often developed academic settings absence input research software engineers can aid this transition operational efficiency sustainability. have few practical ways support joint efforts between researchers software engineers skills develop revise research tools robust design, accessibility scalability modern computing platforms. traditional grant funding process emphasized innovation research progress over use software engineering best-practices design principles, are essential reliability sustainability an era large-scale, integrated data. is NIH vision establish modernized integrated biomedical data ecosystem adopts latest data science technologies, including cloud computing, best practice guidelines arising community consensus, such the FAIR principles open-source development. effort described the NIH Data Science Strategic Plan led the newly established ODSS. addition major efforts IT infrastructure, data resources, workforce development, policy considerations, data science strategic plan includes goals enhance software workflows the modern data ecosystem. Research Objective goal this Notice Special Interest NOSI) to encourage researchers engage new types collaborations focus research software. Supplements support efforts address robustness, sustainability, reusability, scalability existing biomedical research software tools workflows recognized scientific value. efforts expected adhere software engineering best practices design principles take significant steps toward sustainability open source cloud-based environments. broad range projects have significant biomedical research software workflow development components eligible, regardless the scientific area emphasis. scope each proposed project defined and limited the aims the funded project which supplement being sought. Significant software engineering skills expected be needed develop robust implementations to adapt software changing computing paradigms. Thus, supplements primarily intended provide support software engineering staff storage computing costs are required test software revisions. Delivering reliable, sustainable, reusable software across multiple platforms a whole-lifecycle effort, illustrated the following examples. Software development be improved enhancements the development environment, including resources building, testing, community contribution. Engaging community improve robustness making code available appropriate open source licensing. Compliance open interfaces data formats be added enhance interoperability reusability. Refactoring be performed take advantage new hardware compute environments e.g., parallelizing process using standard workflow language can run cloud environments). Reusability be enhanced improving dissemination channels important algorithms tools e.g., inclusion package distribution channels), publication tools shared container registries, by refinement operating manuals. Projects propose test cloud-readiness a local, commercial, public cloud environment. Working the NIH STRIDES initiative https://datascience.nih.gov/strides) strongly encouraged. Cloud readiness a blanket term can encompass range activities. this announcement cloud readiness refers adapting cloud architecture extending usefulness software. Examples produce robust, sustainable cloud-ready research software include, are limited to: Adding APIs services reducing coupling complex shared state Decomposing decoupling services explicitly encoded data sources Employing standard security relies cloud Identity Access Management IAM) models Improving architecture reduce chattiness over network to minimize data ingress/egress charges cloud environments Adopting standard input output data formats Factoring configuration services environment variables configuration properties deployment Implementing standard logging models Converting tools provide clean input, output, configuration make more usable composition via workflow languages such CWL WDL Enhancing source code build/test tools support community open source development, developing standard build packaging tools manage dependencies produce containerized runtimes formatting packages sharing via common package management tools appropriate the language environment Enhancing standard unit functional testing support sample data sets testing patches upgrades supplement application must demonstrate use best software engineering practices design principles. Examples relevant projects address or of challenges toward becoming ready open science cloud environment include, are limited to: Provisioning standard source code structure, documentation, version management, build test support codebases promotes community open source enhancement. Refactoring software incorporate standard interfaces data formats, replacement built-in dependencies standard hardened libraries. Adding APIs services software, especially compliant community standards Refactoring software scale efficiently the cloud. Containerization software entry a tool registry. Enhancing usability, interoperability scalability under increasing load, including making of enhanced hardware clustering technology. Enhancing data security privacy protection. Projects involving significant new scientific features opposed software engineering NOT appropriate this NOSI. Possible exceptions include enhanced data security privacy functions. Projects no active software development components would to add are eligible this NOSI. Application Submission Information Budget be eligible, parent award must able receive funds FY2020 Oct. 1, 2019 - Sept. 30, 2020) not in final year in no-cost extension period the time the award. One-time supplement budget requests cannot exceed 150,000 direct costs. number awards be contingent availability funds receipt meritorious applications. is currently anticipated 6-10 awards be made. Eligible Activity Codes: Administrative supplement requests be submitted the following activity codes: R01, U01, R03, R00, R21, R33, R35, R37, R61 Centers multi-project grant mechanisms not eligible. Additional Information Applications this initiative must submitted using PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) its subsequent reissued equivalent. instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – May 15, 2020 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-OD-20-073" without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B will be considered for initiative. Requests be one year support only. Research Strategy section the application is limited 3 pages. Research Strategy should include justification significant user base cloud readiness’, timelines activities proposed, indication how supplement uses best software engineering practices design principles. Electronic submissions are required for funding opportunity. process Streamlined Submissions using eRA Commons cannot used this initiative. Administrative Evaluation Process Submitted applications must follow guidelines the IC funds parent grant. Administrative Supplements not receive peer review. IC conduct administrative reviews applications submitted their IC separately. most meritorious applications be evaluated a trans-NIH panel NIH staff supported based upon availability funds. criteria described below be considered the administrative evaluation process: the work proposed within scope the active award? the active award be supplemented focused software tool/workflow development, is a significant component the award? Does user base justify additional support? the proposed project technically feasible within supplement's funding period? the proposed timelines adequate realistic? the proposed supplement project focused software engineering robust, sustainable software is cloud ready” opposed enhancing scientific value)? Does project demonstrate sound software development practices, improve performance, interoperability, portability reliability, community engagement, sustainability, adoption? Information: is strongly recommended the applicants contact respective program officers the Institute supporting parent award advance to: Confirm the supplement falls within scope the parent award; Request requirements the IC submitting applications administrative supplements Investigators planning submit application response this NOSI also strongly encouraged contact discuss proposed research/aims the scientific contact listed this NOSI advance the application receipt date. Following submission, applicants strongly encouraged notify program contact the IC supporting parent award a request been submitted response this FOA order facilitate efficient processing the request.   Inquiries Please direct inquiries to: Jessica Mazerik, Ph.D.Office Data Science StrategyDivision Program Coordination, Planning, Strategic InitiativesOffice the DirectorJessica.mazerik@nih.gov  

Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-18-906 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Notice of Special Interest
Tuesday, March 3, 2020
Workforce Diversity
Tuesday, June 30, 2020
333
NOT-NS-20-023

Funding Opportunity Purpose

Notice Special Interest Encourage Eligible NIH HEAL Initiative Awardees Apply PA-18-906 Research Supplements Promote Diversity Health-Related Research Admin Supp - Clinical Trial Allowed) Notice Number: NOT-NS-20-023 Key Dates Release Date: March 3, 2020 First Available Due Date: April 15, 2020 Expiration Date: June 30, 2020 Related Announcements PA-18-906 - Research Supplements Promote Diversity Health-Related Research Admin Supp - Clinical Trial Allowed) Issued National Institute Neurological Disorders Stroke NINDS) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) National Cancer Institute NCI) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Purpose NIH a strong interest the diversity the NIH-funded research enterprise the recently funded NIH notice NOT-OD-20-031) encourages institutions diversify scientific workforce enhancing participation individuals groups identified underrepresented the biomedical, clinical, behavioral, social sciences. Participating institutes continue support efforts through ongoing programs supplement funding opportunities. specific notice reiterates interest encourages eligible grant cooperative agreement awardees the HEAL Initiative community apply administrative supplements response to PA-18-906, Research Supplements Promote Diversity Health-Related Research Admin Supp - Clinical Trial Allowed). notice part the NIH’s Helping End Addiction Long-term HEAL) Initiative speed scientific solutions the national opioid public health crisis. NIH HEAL Initiative bolster research across NIH 1) improve treatment opioid misuse addiction 2) enhance pain management. information the HEAL Initiative available at: https://heal.nih.gov/ Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-906 - Research Supplements Promote Diversity Health-Related Research Admin Supp - Clinical Trial Allowed) instructions the SF424 R&R) Application Guide and PA-18-906 must followed, the following additions: Application Due Date(s) – April 15, 2020 June 1, 2020 5:00 PM local time applicant organization. funding consideration, applicants must include ldquo;NOT-NS-20-023” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Research Strategy section the application limited 6 pages. Only existing awardees the HEAL Initiative program eligible apply. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award well as Alex.Tuttle@nih.gov that request been submitted response this FOA order facilitate efficient processing the request. the first sentence the Research Strategy, applicants requested state the parent grant awarded a HEAL Initiative award to identify specific FOA the parent grant e.g., RFA-NS-19-016) facilitate processing the supplement application. HEAL diversity supplement awardees strongly encouraged participate annual PD/PI meetings in activities their mentors. Applicants request funds, addition the research costs specified in PA-18-906, enable supplement candidate attend annual HEAL Initiative PD/PI meeting the Washington, DC area. request additional funds should reasonable well justified the application. Potential applicants strongly encouraged review the supplemental guidance for diversity supplement applications the NINDS web site. Consultation the Program Official the qualifying HEAL award the individual named under Inquiries below highly recommended. Supplement applications be evaluated the HEAL Initiative diversity committee. Applications non-responsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries to: Eric Hudak, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: Eric.Hudak@nih.gov

Pages